secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016277
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics Q1 net loss $9.1M; cash runway into Q3 2024; advancing EB-101 BLA submission
--------------------------------------------------------------------------------

- Net loss of $9.1M ($0.54 loss per share) vs $22.0M ($3.80) in Q1 2022; license revenue nil.
- Cash, equivalents, short-term investments $40.7M at Mar 31, 2023, down from $52.5M at Dec 31, 2022; cash runway into Q3 2024.
- Progress toward BLA submission for EB-101 in RDEB in late Q2/early Q3 2023; pre-BLA meeting request submitted to FDA.
- Additional Phase 3 VIITAL data presented at ISID; preclinical AAV ophthalmology data (ABO-504, ABO-503, ABO-505) at ASGCT May 16-20.
- R&D expenses $8.0M, G&A $4.0M for Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/0001493152-23-016277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer